Skip to main content
Erschienen in: Archives of Osteoporosis 1/2016

01.12.2016 | Review

A systematic review of intervention thresholds based on FRAX

A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation

verfasst von: John A. Kanis, Nicholas C. Harvey, Cyrus Cooper, Helena Johansson, Anders Odén, Eugene V. McCloskey, The Advisory Board of the National Osteoporosis Guideline Group

Erschienen in: Archives of Osteoporosis | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Summary

This systematic review identified assessment guidelines for osteoporosis that incorporate FRAX. The rationale for intervention thresholds is given in a minority of papers. Intervention thresholds (fixed or age-dependent) need to be country-specific.

Introduction

In most assessment guidelines, treatment for osteoporosis is recommended in individuals with prior fragility fractures, especially fractures at spine and hip. However, for those without prior fractures, the intervention thresholds can be derived using different methods. The aim of this report was to undertake a systematic review of the available information on the use of FRAX® in assessment guidelines, in particular the setting of thresholds and their validation.

Methods

We identified 120 guidelines or academic papers that incorporated FRAX of which 38 provided no clear statement on how the fracture probabilities derived are to be used in decision-making in clinical practice. The remainder recommended a fixed intervention threshold (n = 58), most commonly as a component of more complex guidance (e.g. bone mineral density (BMD) thresholds) or an age-dependent threshold (n = 22). Two guidelines have adopted both age-dependent and fixed thresholds.

Results

Fixed probability thresholds have ranged from 4 to 20 % for a major fracture and 1.3–5 % for hip fracture. More than one half (39) of the 58 publications identified utilised a threshold probability of 20 % for a major osteoporotic fracture, many of which also mention a hip fracture probability of 3 % as an alternative intervention threshold. In nearly all instances, no rationale is provided other than that this was the threshold used by the National Osteoporosis Foundation of the USA. Where undertaken, fixed probability thresholds have been determined from tests of discrimination (Hong Kong), health economic assessment (USA, Switzerland), to match the prevalence of osteoporosis (China) or to align with pre-existing guidelines or reimbursement criteria (Japan, Poland). Age-dependent intervention thresholds, first developed by the National Osteoporosis Guideline Group (NOGG), are based on the rationale that if a woman with a prior fragility fracture is eligible for treatment, then, at any given age, a man or woman with the same fracture probability but in the absence of a previous fracture (i.e. at the ‘fracture threshold’) should also be eligible. Under current NOGG guidelines, based on age-dependent probability thresholds, inequalities in access to therapy arise especially at older ages (≥70 years) depending on the presence or absence of a prior fracture. An alternative threshold using a hybrid model reduces this disparity.

Conclusion

The use of FRAX (fixed or age-dependent thresholds) as the gateway to assessment identifies individuals at high risk more effectively than the use of BMD. However, the setting of intervention thresholds needs to be country-specific.
Anhänge
Nur mit Berechtigung zugänglich
Glossar
Age-dependent threshold
Intervention or assessment threshold of fracture probability that varies with age
Assessment threshold
The fracture probability at which further assessment id recommended (usually BMD)
Fixed threshold
Intervention or assessment threshold of fracture probability that is fixed over all ages
Fracture threshold
The average probability of fracture for a specific age
Hybrid threshold
Intervention or assessment threshold of fracture probability that partly varies with age and is partly fixed
Intervention threshold
For this report, the fracture probability at which treatment is recommended
Major osteoporotic fracture
Fracture of hip, spine (clinical), distal forearm or humerus.
NOGG strategy
The strategy that describes intervention or assessment threshold of fracture probability that varies with age
Osteopenia
In this report, BMD defined: a T-score of between −1 and −2.5
Osteoporosis
In this report, BMD defined: a T-score of <−2.5
Literatur
1.
Zurück zum Zitat Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733PubMedCrossRef Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733PubMedCrossRef
2.
Zurück zum Zitat Hernlund E, Svedbom A, Ivergård M et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136PubMedPubMedCentralCrossRef Hernlund E, Svedbom A, Ivergård M et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767–778PubMedCrossRef Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767–778PubMedCrossRef
5.
Zurück zum Zitat Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936PubMedCrossRef Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936PubMedCrossRef
6.
7.
Zurück zum Zitat Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989–995PubMedCrossRef Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989–995PubMedCrossRef
8.
Zurück zum Zitat Kanis JA, on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. Accessed https://www.shef.ac.uk/FRAX/reference.aspx 14 July 2015 Kanis JA, on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. Accessed https://​www.​shef.​ac.​uk/​FRAX/​reference.​aspx 14 July 2015
9.
Zurück zum Zitat Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 344:e3427. doi:10.1136/bmj.e3427 PubMedCrossRef Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 344:e3427. doi:10.​1136/​bmj.​e3427 PubMedCrossRef
10.
Zurück zum Zitat Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 19:1431–1444PubMedCrossRef Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 19:1431–1444PubMedCrossRef
12.
Zurück zum Zitat Kanis JA, Compston J, Cooper C et al (2016) SIGN guidelines for Scotland. BMD vs. FRAX vs. QFracture. Calcif Tissue Int 98:417–425PubMedCrossRef Kanis JA, Compston J, Cooper C et al (2016) SIGN guidelines for Scotland. BMD vs. FRAX vs. QFracture. Calcif Tissue Int 98:417–425PubMedCrossRef
13.
Zurück zum Zitat Collins GS, Mallett S, Altman DG (2011) Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFractureScores. BMJ 342:d3651PubMedPubMedCentralCrossRef Collins GS, Mallett S, Altman DG (2011) Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFractureScores. BMJ 342:d3651PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046PubMedCrossRef Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046PubMedCrossRef
15.
Zurück zum Zitat Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2012) FRAX with and without BMD. Calcif Tissue Int 90:1–13PubMedCrossRef Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2012) FRAX with and without BMD. Calcif Tissue Int 90:1–13PubMedCrossRef
16.
Zurück zum Zitat Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238PubMedCrossRef Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238PubMedCrossRef
17.
Zurück zum Zitat Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl D, Cyrus Cooper C, on behalf of the IOF Working Group on Epidemiology and Quality of Life (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23:2239–2256PubMedPubMedCentralCrossRef Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl D, Cyrus Cooper C, on behalf of the IOF Working Group on Epidemiology and Quality of Life (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23:2239–2256PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Kanis JA, Hans D, Cooper C et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411PubMedCrossRef Kanis JA, Hans D, Cooper C et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411PubMedCrossRef
19.
Zurück zum Zitat Middleton RG, Shabani F, Uzoigwe CE, Shoaib A, Moqsith M, Venkatesan M (2012) FRAX and the assessment of the risk of developing a fragility fracture. J Bone Joint Surg 94B:1313–1320 Middleton RG, Shabani F, Uzoigwe CE, Shoaib A, Moqsith M, Venkatesan M (2012) FRAX and the assessment of the risk of developing a fragility fracture. J Bone Joint Surg 94B:1313–1320
20.
Zurück zum Zitat Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809–816PubMedCrossRef Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809–816PubMedCrossRef
21.
Zurück zum Zitat Leslie WD, Lix LM, Johansson H, Oden A, McLoskey EV, Kanis JA, for the Manitoba Bone Density Program (2011) Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 22:839–847PubMedCrossRef Leslie WD, Lix LM, Johansson H, Oden A, McLoskey EV, Kanis JA, for the Manitoba Bone Density Program (2011) Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 22:839–847PubMedCrossRef
22.
Zurück zum Zitat Johansson H, Kanis JA, Odén A et al (2014) Impact of femoral neck and lumbar spine BMD discordances on FRAX probabilities in women: a meta-analysis of international cohorts. Calcif Tissue Int 95:428–435PubMedPubMedCentralCrossRef Johansson H, Kanis JA, Odén A et al (2014) Impact of femoral neck and lumbar spine BMD discordances on FRAX probabilities in women: a meta-analysis of international cohorts. Calcif Tissue Int 95:428–435PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Leslie WD, Johansson H, Kanis JA, Lamy O, Oden A, McCloskey EV, Hans D (2014) Lumbar spine texture enhances ten-year fracture probability assessment. Osteoporos Int 25:2271–2277PubMedCrossRef Leslie WD, Johansson H, Kanis JA, Lamy O, Oden A, McCloskey EV, Hans D (2014) Lumbar spine texture enhances ten-year fracture probability assessment. Osteoporos Int 25:2271–2277PubMedCrossRef
24.
Zurück zum Zitat McCloskey EV, Odén A, Harvey NC et al (2015) Adjusting fracture probability by trabecular bone score. Calcif Tissue Int 96:500–509PubMedCrossRef McCloskey EV, Odén A, Harvey NC et al (2015) Adjusting fracture probability by trabecular bone score. Calcif Tissue Int 96:500–509PubMedCrossRef
25.
Zurück zum Zitat McCloskey EV, Odén A, Harvey NC et al (2016) A meta-analysis of trabecular bone score in fracture risk prediction and its dependence on FRAX. J Bone Miner Res 31:940–948PubMedCrossRef McCloskey EV, Odén A, Harvey NC et al (2016) A meta-analysis of trabecular bone score in fracture risk prediction and its dependence on FRAX. J Bone Miner Res 31:940–948PubMedCrossRef
26.
27.
Zurück zum Zitat Masud T, Binkley N, Boonen S, Hannan MT, FRAX® Position Development Conference Members (2011) Official Positions for FRAX® clinical regarding falls and frailty: can falls and frailty be used in FRAX®? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 14:194–204PubMedCrossRef Masud T, Binkley N, Boonen S, Hannan MT, FRAX® Position Development Conference Members (2011) Official Positions for FRAX® clinical regarding falls and frailty: can falls and frailty be used in FRAX®? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 14:194–204PubMedCrossRef
28.
Zurück zum Zitat Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y, on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation ( IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57PubMedCrossRef Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y, on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation ( IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57PubMedCrossRef
29.
Zurück zum Zitat Papaioannou A, Morin S, Cheung AM et al (2010) (2010) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873PubMedPubMedCentralCrossRef Papaioannou A, Morin S, Cheung AM et al (2010) (2010) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Dawson-Hughes B, National Osteoporosis Foundation Guide Committee (2008) A revised clinician’s guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 93:2463–2465PubMedCrossRef Dawson-Hughes B, National Osteoporosis Foundation Guide Committee (2008) A revised clinician’s guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 93:2463–2465PubMedCrossRef
31.
Zurück zum Zitat Orimo H, Nakamura T, Hosoi T et al (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. Arch Osteoporos 7:3–20PubMedPubMedCentralCrossRef Orimo H, Nakamura T, Hosoi T et al (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. Arch Osteoporos 7:3–20PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Scottish Intercollegiate Guidelines Network (SIGN) (2015) Management of osteoporosis and the prevention of fragility fractures. Edinburgh: SIGN; 2015. (SIGN publication no. 142). [March 2015]. Available from URL: http://www.sign.ac.uk accessed 11 May 2015 Scottish Intercollegiate Guidelines Network (SIGN) (2015) Management of osteoporosis and the prevention of fragility fractures. Edinburgh: SIGN; 2015. (SIGN publication no. 142). [March 2015]. Available from URL: http://​www.​sign.​ac.​uk accessed 11 May 2015
33.
Zurück zum Zitat Schurman L, Bagur A, Claus-Hemberg H, Messina OD et al (2013) Guias 2012 para el diagnostico, la prevencion y el tratamiento de la osteoporosis. Medicina (Buenos Aires) 73:55–74 Schurman L, Bagur A, Claus-Hemberg H, Messina OD et al (2013) Guias 2012 para el diagnostico, la prevencion y el tratamiento de la osteoporosis. Medicina (Buenos Aires) 73:55–74
34.
Zurück zum Zitat Wu CH, McCloskey EV, Lee JK et al (2014) Consensus of official position of IOF/ISCD FRAX initiatives in Asia-Pacific region. J Clin Densitom 17:150–155PubMedCrossRef Wu CH, McCloskey EV, Lee JK et al (2014) Consensus of official position of IOF/ISCD FRAX initiatives in Asia-Pacific region. J Clin Densitom 17:150–155PubMedCrossRef
35.
Zurück zum Zitat Pereira RM, Carvalho JF, Paula AP et al (2012) Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol 52:580–593, English, Portuguese PubMedCrossRef Pereira RM, Carvalho JF, Paula AP et al (2012) Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol 52:580–593, English, Portuguese PubMedCrossRef
37.
Zurück zum Zitat Fouda MA, Khan AA, Sultan MS, Rios LP, McAssey K, Armstrong D (2012) Evaluation and management of skeletal health in celiac disease: position statement. Can J Gastroenterol 26:819–829PubMedPubMedCentralCrossRef Fouda MA, Khan AA, Sultan MS, Rios LP, McAssey K, Armstrong D (2012) Evaluation and management of skeletal health in celiac disease: position statement. Can J Gastroenterol 26:819–829PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Zhang Z, Gao B, Liu Z (2012) Fracture risk assessment tool (FRAX) for osteoporosis diagnosis and treatment. Chin J Osteoporos 18:589–595 Zhang Z, Gao B, Liu Z (2012) Fracture risk assessment tool (FRAX) for osteoporosis diagnosis and treatment. Chin J Osteoporos 18:589–595
39.
Zurück zum Zitat Curković B, Grazio S, Babić-Naglić D, Anić B, Vlak T, Hanih M (2008) Recommendations of the Croatian Society for Rheumatology for prevention, diagnostics and treatment of post-menopausal osteoporosis. Reumatizam 55:26–30, Croatian Curković B, Grazio S, Babić-Naglić D, Anić B, Vlak T, Hanih M (2008) Recommendations of the Croatian Society for Rheumatology for prevention, diagnostics and treatment of post-menopausal osteoporosis. Reumatizam 55:26–30, Croatian
40.
Zurück zum Zitat Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J, on behalf of the ESMO Guidelines Working Group (2014) Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 25(suppl 3):124–137CrossRef Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J, on behalf of the ESMO Guidelines Working Group (2014) Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 25(suppl 3):124–137CrossRef
41.
Zurück zum Zitat Brincat M, Calleja-Agius J, Erel CT et al (2011) EMAS position statement: bone densitometry screening for osteoporosis. Maturitas 68:98–101PubMedCrossRef Brincat M, Calleja-Agius J, Erel CT et al (2011) EMAS position statement: bone densitometry screening for osteoporosis. Maturitas 68:98–101PubMedCrossRef
42.
Zurück zum Zitat Duru N, van der Goes MC, Jacobs JW et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72:1905–1913PubMedCrossRef Duru N, van der Goes MC, Jacobs JW et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72:1905–1913PubMedCrossRef
43.
Zurück zum Zitat Cortet B, Lartigau E, Caty A et al (2012) Androgen deprivation therapy for prostate cancer and osteoporotic risk. Progres En Urologie 22:S31–S38PubMedCrossRef Cortet B, Lartigau E, Caty A et al (2012) Androgen deprivation therapy for prostate cancer and osteoporotic risk. Progres En Urologie 22:S31–S38PubMedCrossRef
45.
Zurück zum Zitat Osteoporosis Society of Hong Kong (2013) OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. Hong Kong Med J 19(suppl 2):3–40 Osteoporosis Society of Hong Kong (2013) OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. Hong Kong Med J 19(suppl 2):3–40
47.
Zurück zum Zitat Lewiecki EM, Compston JE, Miller PD et al (2011) Official Positions for FRAX® bone mineral density and FRAX® simplification. From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 14:226–236PubMedCrossRef Lewiecki EM, Compston JE, Miller PD et al (2011) Official Positions for FRAX® bone mineral density and FRAX® simplification. From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 14:226–236PubMedCrossRef
49.
Zurück zum Zitat Adami S, Bertoldo F, Brandi ML (2009) Linee guida per la diagnosi, prevenzione e terapia dell’osteoporosi [Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo 61:260–284PubMed Adami S, Bertoldo F, Brandi ML (2009) Linee guida per la diagnosi, prevenzione e terapia dell’osteoporosi [Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo 61:260–284PubMed
50.
Zurück zum Zitat Maalouf G, Bachour F, Issa M et al (2012) Guidelines for fragility fracture in Lebanon. J Med Liban 60:153–158PubMed Maalouf G, Bachour F, Issa M et al (2012) Guidelines for fragility fracture in Lebanon. J Med Liban 60:153–158PubMed
54.
Zurück zum Zitat Peña-Ríos DH, Cisneros-Dreinhofer FA, del Pilar De la Peña-Rodríguez M et al (2015) Consenso de diagnóstico y tratamiento de la osteoporosis en la mujer posmenopáusica mexicana [Consensus for diagnosis and treatment in Mexican women with postmenopausal osteoporosis]. Med Int Méx 31:596–610 Peña-Ríos DH, Cisneros-Dreinhofer FA, del Pilar De la Peña-Rodríguez M et al (2015) Consenso de diagnóstico y tratamiento de la osteoporosis en la mujer posmenopáusica mexicana [Consensus for diagnosis and treatment in Mexican women with postmenopausal osteoporosis]. Med Int Méx 31:596–610
55.
Zurück zum Zitat Dutch Institute for Healthcare Improvement (CBO) (2011) Richtlijn Osteoporose en fractuurpreventie, derde herziening. CBO, Utrecht Dutch Institute for Healthcare Improvement (CBO) (2011) Richtlijn Osteoporose en fractuurpreventie, derde herziening. CBO, Utrecht
56.
Zurück zum Zitat Romanian Ministry of Health (2010) Guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Order number 1322/2010. (www.ms.ro). Accessed 13 March 2015 Romanian Ministry of Health (2010) Guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Order number 1322/2010. (www.​ms.​ro). Accessed 13 March 2015
57.
Zurück zum Zitat Czerwiński E, Badurski J, Lorenc R, Osieleniec J (2010) Guidelines on the diagnosis of osteoporosis and assessment of fracture risk in Poland. Ortop Traumatol Rehabil 12(2):194–200, English, [Polish] PubMed Czerwiński E, Badurski J, Lorenc R, Osieleniec J (2010) Guidelines on the diagnosis of osteoporosis and assessment of fracture risk in Poland. Ortop Traumatol Rehabil 12(2):194–200, English, [Polish] PubMed
58.
Zurück zum Zitat Al-Saleh Y, Sulimani R, Sabico S et al (2015) Guidelines for osteoporosis in Saudi Arabia: recommendations from the Saudi Osteoporosis Society. Ann Saudi Med 35:1–12PubMed Al-Saleh Y, Sulimani R, Sabico S et al (2015) Guidelines for osteoporosis in Saudi Arabia: recommendations from the Saudi Osteoporosis Society. Ann Saudi Med 35:1–12PubMed
60.
Zurück zum Zitat Ministry of Health (2010) Osteoporosis: Ministry of Health Practice Guidelines. Ministry of Health, Singapore Ministry of Health (2010) Osteoporosis: Ministry of Health Practice Guidelines. Ministry of Health, Singapore
61.
Zurück zum Zitat Rabar S, Lau R, O’Flynn N, Li L, Barry P, on behalf of the Guideline Development Group (2012) Risk assessment of fragility fractures: summary of NICE guidance. BMJ 345:e3698PubMedCrossRef Rabar S, Lau R, O’Flynn N, Li L, Barry P, on behalf of the Guideline Development Group (2012) Risk assessment of fragility fractures: summary of NICE guidance. BMJ 345:e3698PubMedCrossRef
62.
Zurück zum Zitat American Association of Clinical Endocrinologists (2010) Medial guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 16(suppl 3):1–37 American Association of Clinical Endocrinologists (2010) Medial guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 16(suppl 3):1–37
64.
Zurück zum Zitat Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK (2008) Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149:404–415PubMedCrossRef Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK (2008) Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149:404–415PubMedCrossRef
65.
Zurück zum Zitat Lim LS, Hoeksma LJ, Sherin K (2009) Screening for osteoporosis in the adult US population: ACPM position statement on preventive practice. Am J Prev Med 36:366–375PubMedCrossRef Lim LS, Hoeksma LJ, Sherin K (2009) Screening for osteoporosis in the adult US population: ACPM position statement on preventive practice. Am J Prev Med 36:366–375PubMedCrossRef
68.
Zurück zum Zitat Socialstyrelsen (2010) Nationella riktlinjer för rörelseorganens sjukdomar 2010—stöd för styrning och ledning. Preliminär version. Artikelnr 2010-11-15. Published at www.socialstyrelsen.se Accessed 3 Nov 2015 Socialstyrelsen (2010) Nationella riktlinjer för rörelseorganens sjukdomar 2010—stöd för styrning och ledning. Preliminär version. Artikelnr 2010-11-15. Published at www.​socialstyrelsen.​se Accessed 3 Nov 2015
70.
Zurück zum Zitat Arznei & Vernunft (2010) Osteoporose. Knochenbruch- Krankheit. Pharmig, Verband der pharmazeutischen Industrie Österreichs Arznei & Vernunft (2010) Osteoporose. Knochenbruch- Krankheit. Pharmig, Verband der pharmazeutischen Industrie Österreichs
72.
Zurück zum Zitat British Columbia Medical Association (2012) Osteoporosis: diagnosis, treatment and fracture prevention. British Columbia Medical Association and British Columbia Ministry of health British Columbia Medical Association (2012) Osteoporosis: diagnosis, treatment and fracture prevention. British Columbia Medical Association and British Columbia Ministry of health
73.
Zurück zum Zitat Khan A, Fortier M (2014) Osteoporosis in menopause. J Obstet Gynaecol Can 36(9):S1–S15CrossRef Khan A, Fortier M (2014) Osteoporosis in menopause. J Obstet Gynaecol Can 36(9):S1–S15CrossRef
74.
Zurück zum Zitat Zhang Z, Ou Y, Sheng Z, Liao E (2014) How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women. Endocrine 45:195–197PubMedCrossRef Zhang Z, Ou Y, Sheng Z, Liao E (2014) How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women. Endocrine 45:195–197PubMedCrossRef
75.
Zurück zum Zitat Stepan J (2009) Algorithm of treatment of glucocorticoid induced osteoporosis—search for criteria. Vnitr Lek 55:448–454PubMed Stepan J (2009) Algorithm of treatment of glucocorticoid induced osteoporosis—search for criteria. Vnitr Lek 55:448–454PubMed
76.
Zurück zum Zitat Rizzoli R, Body JJ, DeCensi A, Reginster JY, Piscitelli P, Brandi ML (2012) Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int 23:2567–2576, and erratum Osteoporos Int 23: 2577 PubMedCrossRef Rizzoli R, Body JJ, DeCensi A, Reginster JY, Piscitelli P, Brandi ML (2012) Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int 23:2567–2576, and erratum Osteoporos Int 23: 2577 PubMedCrossRef
78.
Zurück zum Zitat Makras P, Paiopoulos G, Lyritis GP (2012) 2011 Guidelines for the diagnosis and treatment of osteoporosis in Greece. J Musculoskelet Neuronal Interact 12:38–42PubMed Makras P, Paiopoulos G, Lyritis GP (2012) 2011 Guidelines for the diagnosis and treatment of osteoporosis in Greece. J Musculoskelet Neuronal Interact 12:38–42PubMed
79.
Zurück zum Zitat Makras P, Athanasakis K, Boubouchairopoulou N et al (2015) Cost-effective osteoporosis treatment thresholds in Greece. Osteoporos Int 26:1949–1957PubMedCrossRef Makras P, Athanasakis K, Boubouchairopoulou N et al (2015) Cost-effective osteoporosis treatment thresholds in Greece. Osteoporos Int 26:1949–1957PubMedCrossRef
80.
Zurück zum Zitat Cheung E, Kung AWC, Tan KCB (2014) Outcomes of applying the NOF, NOGG and Taiwanese guidelines to a cohort of Chinese early postmenopausal women. Clin Endocrinol 80:200–207CrossRef Cheung E, Kung AWC, Tan KCB (2014) Outcomes of applying the NOF, NOGG and Taiwanese guidelines to a cohort of Chinese early postmenopausal women. Clin Endocrinol 80:200–207CrossRef
81.
Zurück zum Zitat Lakatos P, Szekeres L, Takács I et al (2011) Diagnostic and therapeutic guidelines for the age-related and glucocorticoid-induced osteoporosis—2011, Hungary. Magyar Reumatol 1:28–33, Hungarian Lakatos P, Szekeres L, Takács I et al (2011) Diagnostic and therapeutic guidelines for the age-related and glucocorticoid-induced osteoporosis—2011, Hungary. Magyar Reumatol 1:28–33, Hungarian
82.
Zurück zum Zitat Nakatoah S, Takemaru Y (2013) Application of the fracture risk assessment tool (FRAX®) and determination of suitable cut-off values during primary screening I specific health check-ups in Japan. J Bone Miner Metab 31:674–680CrossRef Nakatoah S, Takemaru Y (2013) Application of the fracture risk assessment tool (FRAX®) and determination of suitable cut-off values during primary screening I specific health check-ups in Japan. J Bone Miner Metab 31:674–680CrossRef
85.
Zurück zum Zitat Yeap SS, Hew FL, Lee JK et al (2013) The Malaysian clinical guidance on the management of postmenopausal osteoporosis, 2012: a summary. Int J Rheum Dis 16:30–40PubMedCrossRef Yeap SS, Hew FL, Lee JK et al (2013) The Malaysian clinical guidance on the management of postmenopausal osteoporosis, 2012: a summary. Int J Rheum Dis 16:30–40PubMedCrossRef
86.
Zurück zum Zitat Cymet-Ramírez J, Cisneros-Dreinhofer FA, Alvarez-Martínez MM et al (2011) Diagnosis and treatment of osteoporosis. Position of the Mexican College of Orthopedics and Traumatology. Acta Ortop Mex 25:303–312, Spanish PubMed Cymet-Ramírez J, Cisneros-Dreinhofer FA, Alvarez-Martínez MM et al (2011) Diagnosis and treatment of osteoporosis. Position of the Mexican College of Orthopedics and Traumatology. Acta Ortop Mex 25:303–312, Spanish PubMed
87.
Zurück zum Zitat Li-Yu J, Perez EC, Cañete A, Bonifacio L et al (2011) Clinical Practice Guidelines Task Force Committee on Osteoporosis. Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines. Int J Rheum Dis 14:223–238PubMedCrossRef Li-Yu J, Perez EC, Cañete A, Bonifacio L et al (2011) Clinical Practice Guidelines Task Force Committee on Osteoporosis. Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines. Int J Rheum Dis 14:223–238PubMedCrossRef
88.
Zurück zum Zitat Badurski JE, Kanis JA, Johansson H et al (2011) The application of FRAX (R) to determine intervention thresholds in osteoporosis treatment in Poland. Pol Arch Med Wewn 121:148–154PubMed Badurski JE, Kanis JA, Johansson H et al (2011) The application of FRAX (R) to determine intervention thresholds in osteoporosis treatment in Poland. Pol Arch Med Wewn 121:148–154PubMed
89.
Zurück zum Zitat Lorenc R, Głuszko P, Karczmarewicz E et al (2011) Polish recommendations on the diagnosis and treatment of osteoporosis. Medycyna Praktyczna(Reumatologia) Special Edition 1/2011 [Polish] Lorenc R, Głuszko P, Karczmarewicz E et al (2011) Polish recommendations on the diagnosis and treatment of osteoporosis. Medycyna Praktyczna(Reumatologia) Special Edition 1/2011 [Polish]
90.
Zurück zum Zitat Badurski J, Jeziernicka E, Dobrenko A et al (2011) The characteristics of osteoporotic fractures in the region of Bialystok (BOS-2). The application of the WHO algorithm, FRAX (R) BMI and FRAX (R) BMD assessment tools to determine patients for intervention. Endokrynol Pol 62:290–298PubMed Badurski J, Jeziernicka E, Dobrenko A et al (2011) The characteristics of osteoporotic fractures in the region of Bialystok (BOS-2). The application of the WHO algorithm, FRAX (R) BMI and FRAX (R) BMD assessment tools to determine patients for intervention. Endokrynol Pol 62:290–298PubMed
91.
Zurück zum Zitat Gluszko P, Lorenc RS, Karczmarewicz E, Misiorowski W, Jaworski M (2014) Polish guidelines for the diagnosis and management of osteoporosis: a review of 2013 update. Pol Arch Med Wewn 124:255–263PubMed Gluszko P, Lorenc RS, Karczmarewicz E, Misiorowski W, Jaworski M (2014) Polish guidelines for the diagnosis and management of osteoporosis: a review of 2013 update. Pol Arch Med Wewn 124:255–263PubMed
92.
Zurück zum Zitat Goncalves MJ, Rodrigues AM, Canhao H, Fonseca JE (2013) Osteoporosis: from bone biology to individual treatment decision. Acta Med Port 26:445–455PubMed Goncalves MJ, Rodrigues AM, Canhao H, Fonseca JE (2013) Osteoporosis: from bone biology to individual treatment decision. Acta Med Port 26:445–455PubMed
93.
Zurück zum Zitat Amin TT, Al Owaifeer A, Al-Hashim H et al (2013) Osteoporosis among older Saudis: risk of fractures and unmet needs. Arch Osteoporos 8:118PubMedCrossRef Amin TT, Al Owaifeer A, Al-Hashim H et al (2013) Osteoporosis among older Saudis: risk of fractures and unmet needs. Arch Osteoporos 8:118PubMedCrossRef
94.
Zurück zum Zitat Niemethova E, Killinger Z, Payer J (2013) Fracture risk prediction with FRAX in Slovak postmenopausal women. Cent Eur J Med 8:571–586 Niemethova E, Killinger Z, Payer J (2013) Fracture risk prediction with FRAX in Slovak postmenopausal women. Cent Eur J Med 8:571–586
95.
Zurück zum Zitat Kocjan T, Prezelj J, Pfeifer M, Sever MJ, Cokolic M, Zavratnik A (2013) Guidelines for the detection and treatment of osteoporosis. Zdrav Vestn 82:207–217 Kocjan T, Prezelj J, Pfeifer M, Sever MJ, Cokolic M, Zavratnik A (2013) Guidelines for the detection and treatment of osteoporosis. Zdrav Vestn 82:207–217
97.
Zurück zum Zitat Hough S, Ascott-Evans B-H, Brown SL et al for the National Osteoporosis Foundation of South Africa (NOFSA) (2010) NOFSA guideline for the diagnosis and management of osteoporosis. Available online at: www.jemdsa.co.za and www.osteoporosis.org.za Accessed 22 Oct 2015 Hough S, Ascott-Evans B-H, Brown SL et al for the National Osteoporosis Foundation of South Africa (NOFSA) (2010) NOFSA guideline for the diagnosis and management of osteoporosis. Available online at: www.jemdsa.co.za and www.osteoporosis.org.za Accessed 22 Oct 2015
98.
Zurück zum Zitat Kim JW, Jeon YJ, Baek DH, Kim TN, Chang JS (2014) Percentage of the population at high risk of osteoporotic fracture in South Korea: analysis of the 2010 Fifth Korean National Health and Nutrition Examination survey data. Osteoporos Int 25:1313–1319PubMedCrossRef Kim JW, Jeon YJ, Baek DH, Kim TN, Chang JS (2014) Percentage of the population at high risk of osteoporotic fracture in South Korea: analysis of the 2010 Fifth Korean National Health and Nutrition Examination survey data. Osteoporos Int 25:1313–1319PubMedCrossRef
99.
Zurück zum Zitat Pérez Edo L, Alonso Ruiz A, Roig Vilaseca D, Spanish Society of Rheumatology et al (2011) 2011 Up-date of the consensus statement of the Spanish Society of Rheumatology on osteoporosis. Reumatol Clin 7:357–379, Spanish Pérez Edo L, Alonso Ruiz A, Roig Vilaseca D, Spanish Society of Rheumatology et al (2011) 2011 Up-date of the consensus statement of the Spanish Society of Rheumatology on osteoporosis. Reumatol Clin 7:357–379, Spanish
100.
Zurück zum Zitat Etxebarria-Foronda I, Caeiro-Rey JR, Larrainzar-Garijo R et al (2015) Guía SECOT-GEIOS en osteoporosis y fractura por fragilidad. Actualización. Rev Esp Cir Ortop Traumatol 59:373–393PubMed Etxebarria-Foronda I, Caeiro-Rey JR, Larrainzar-Garijo R et al (2015) Guía SECOT-GEIOS en osteoporosis y fractura por fragilidad. Actualización. Rev Esp Cir Ortop Traumatol 59:373–393PubMed
101.
Zurück zum Zitat García R, Jódar Gimeno E, García Martín A et al (2012) Clinical practice guidelines for evaluation and treatment of osteoporosis associated to endocrine and nutritional conditions. Bone Metabolism Working Group of the Spanish Society of Endocrinology. Endocrinol Nutr 59:174–196, Erratum in: Endocrinol Nutr. 2012 59: 469 CrossRef García R, Jódar Gimeno E, García Martín A et al (2012) Clinical practice guidelines for evaluation and treatment of osteoporosis associated to endocrine and nutritional conditions. Bone Metabolism Working Group of the Spanish Society of Endocrinology. Endocrinol Nutr 59:174–196, Erratum in: Endocrinol Nutr. 2012 59: 469 CrossRef
102.
Zurück zum Zitat Lekamwasam S (2013) Sri Lankan FRAX model and country-specific intervention thresholds. Arch Osteoporos 8:148PubMedCrossRef Lekamwasam S (2013) Sri Lankan FRAX model and country-specific intervention thresholds. Arch Osteoporos 8:148PubMedCrossRef
103.
Zurück zum Zitat Johansson H, Kanis JA, Ljunggren O, Strom O, Svensson O, Mellstrom D (2011) FRAX—model for 10-year fracture risk assessment. Support in the treatment of osteoporosis, according to preliminary Swedish guidelines. Lakartidningen 108:336–339PubMed Johansson H, Kanis JA, Ljunggren O, Strom O, Svensson O, Mellstrom D (2011) FRAX—model for 10-year fracture risk assessment. Support in the treatment of osteoporosis, according to preliminary Swedish guidelines. Lakartidningen 108:336–339PubMed
104.
Zurück zum Zitat Lippuner K, Johansson H, Borgström F et al (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporos Int 23:2579–2589PubMedCrossRef Lippuner K, Johansson H, Borgström F et al (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporos Int 23:2579–2589PubMedCrossRef
106.
Zurück zum Zitat Pongchaiyakul C, Leerapun T, Wongsiri S, Songpattanasilp T, Taechakraichana N (2012) Value and validation of RCOST and TOPF clinical practice guideline for osteoporosis treatment. J Med Assoc Thai 95:1528–1535PubMed Pongchaiyakul C, Leerapun T, Wongsiri S, Songpattanasilp T, Taechakraichana N (2012) Value and validation of RCOST and TOPF clinical practice guideline for osteoporosis treatment. J Med Assoc Thai 95:1528–1535PubMed
107.
Zurück zum Zitat Davis S, Martyn-St James M, Sanderson J, et al (2015) Bisphosphonates for preventing osteoporotic fragility fractures (including a partial update of NICE technology appraisal guidance 160 and 161).Technology Assessment Report commissioned by the NIHR HTA Programme on behalf of the National Institute for Health and Care Excellence. Produced by ScHARR, The University of Sheffield Davis S, Martyn-St James M, Sanderson J, et al (2015) Bisphosphonates for preventing osteoporotic fragility fractures (including a partial update of NICE technology appraisal guidance 160 and 161).Technology Assessment Report commissioned by the NIHR HTA Programme on behalf of the National Institute for Health and Care Excellence. Produced by ScHARR, The University of Sheffield
108.
Zurück zum Zitat McCloskey E, Kanis JA, Johansson H et al (2015) FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK. Osteoporos Int 26:2091–2099PubMedCrossRef McCloskey E, Kanis JA, Johansson H et al (2015) FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK. Osteoporos Int 26:2091–2099PubMedCrossRef
109.
Zurück zum Zitat Lyell V, Henderson E, Devine M, Gregson C (2015) Assessment and management of fracture risk in patients with Parkinson’s disease. Age Ageing 44:34–41PubMedCrossRef Lyell V, Henderson E, Devine M, Gregson C (2015) Assessment and management of fracture risk in patients with Parkinson’s disease. Age Ageing 44:34–41PubMedCrossRef
110.
111.
Zurück zum Zitat Nelson HD, Haney EM, Chou R, Dana T, Fu R, Bougatsos C (2010) Screening for osteoporosis: systematic review to update the 2002 US Preventive Services Task Force Recommendation. Evidence Syntheses No. 77. AHRQ Publication No. 10-05145-EF-1. Nelson HD, Haney EM, Chou R, Dana T, Fu R, Bougatsos C (2010) Screening for osteoporosis: systematic review to update the 2002 US Preventive Services Task Force Recommendation. Evidence Syntheses No. 77. AHRQ Publication No. 10-05145-EF-1.
112.
Zurück zum Zitat Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arth Care Res 62:1515–1526CrossRef Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arth Care Res 62:1515–1526CrossRef
113.
Zurück zum Zitat Watts NB, Adler RA, Bilezikian JP et al (2012) Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97:1802–1822PubMedCrossRef Watts NB, Adler RA, Bilezikian JP et al (2012) Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97:1802–1822PubMedCrossRef
114.
Zurück zum Zitat Scillitani A, Mazziotti G, Di Somma C et al (2014) Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int 25:441–446PubMedCrossRef Scillitani A, Mazziotti G, Di Somma C et al (2014) Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int 25:441–446PubMedCrossRef
115.
Zurück zum Zitat American College of Obstetricians and Gynecologists (ACOG). Osteoporosis. Washington (DC): American College of Obstetricians and Gynecologists (AC OG); 2012 Sep. 17. p. (ACOG practice bulletin; no. 129) American College of Obstetricians and Gynecologists (ACOG). Osteoporosis. Washington (DC): American College of Obstetricians and Gynecologists (AC OG); 2012 Sep. 17. p. (ACOG practice bulletin; no. 129)
116.
Zurück zum Zitat North American Menopause Society (NAMS) (2010) Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17:25–54CrossRef North American Menopause Society (NAMS) (2010) Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17:25–54CrossRef
117.
Zurück zum Zitat Sweet MG, Sweet JM, Jeremiah MP, Galaska SS (2008) Diagnosis and treatment of osteoporosis. Am Fam Physician 79:193–200 Sweet MG, Sweet JM, Jeremiah MP, Galaska SS (2008) Diagnosis and treatment of osteoporosis. Am Fam Physician 79:193–200
118.
Zurück zum Zitat Adler RA, Hastings FW, Petkov VI (2010) Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX. Osteoporos Int 21:647–653PubMedCrossRef Adler RA, Hastings FW, Petkov VI (2010) Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX. Osteoporos Int 21:647–653PubMedCrossRef
119.
Zurück zum Zitat Gralow JR, Biermann JS, Farooki A et al (2009) NCCN task force report: bone health in cancer care. J Natl Compr Cancer Netw 7:S1–S32 Gralow JR, Biermann JS, Farooki A et al (2009) NCCN task force report: bone health in cancer care. J Natl Compr Cancer Netw 7:S1–S32
120.
Zurück zum Zitat Jeremiah MP, Unwin BK, Greenawald MH, Casiano VE (2015) Diagnosis and management of osteoporosis. Am Fam Physician 92:261–268PubMed Jeremiah MP, Unwin BK, Greenawald MH, Casiano VE (2015) Diagnosis and management of osteoporosis. Am Fam Physician 92:261–268PubMed
123.
Zurück zum Zitat Tosteson AN, Melton LJ 3rd, Dawson-Hughes B et al (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447PubMedPubMedCentralCrossRef Tosteson AN, Melton LJ 3rd, Dawson-Hughes B et al (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447PubMedPubMedCentralCrossRef
124.
Zurück zum Zitat Berry SD, Kiel DP, Donaldson MG et al (2010) Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study. Osteoporos Int 21:53–60PubMedPubMedCentralCrossRef Berry SD, Kiel DP, Donaldson MG et al (2010) Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study. Osteoporos Int 21:53–60PubMedPubMedCentralCrossRef
125.
Zurück zum Zitat Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd (2010) The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 21:41–52PubMedCrossRef Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd (2010) The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 21:41–52PubMedCrossRef
126.
Zurück zum Zitat Crandall CJ, Larson J, Gourlay M et al (2014) Osteoporosis screening in postmenopausal women 50–64 years-old: Comparison of U.S. Preventive Services Task Force strategy and two traditional strategies in the Women’s Health Initiative. J Bone Miner Res 29:1661–1666PubMedPubMedCentralCrossRef Crandall CJ, Larson J, Gourlay M et al (2014) Osteoporosis screening in postmenopausal women 50–64 years-old: Comparison of U.S. Preventive Services Task Force strategy and two traditional strategies in the Women’s Health Initiative. J Bone Miner Res 29:1661–1666PubMedPubMedCentralCrossRef
127.
Zurück zum Zitat Kanis JA, Harvey N, McCloskey EV (2014) Pre-screening young postmenopausal women for BMD testing. BoneKEy Reports 3, Article number: 544 doi:10.1038/bonekey.39, Published online 11 June 2014 Kanis JA, Harvey N, McCloskey EV (2014) Pre-screening young postmenopausal women for BMD testing. BoneKEy Reports 3, Article number: 544 doi:10.​1038/​bonekey.​39, Published online 11 June 2014
128.
Zurück zum Zitat Lydick E, Cook K, Turpin J, Melton M, Stine R, Byrnes C (1998) Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care 4:37–48PubMed Lydick E, Cook K, Turpin J, Melton M, Stine R, Byrnes C (1998) Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care 4:37–48PubMed
129.
Zurück zum Zitat Koh LK, Sedrine WB, Torralba TP et al (2001) A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporos Int 12:699–705PubMedCrossRef Koh LK, Sedrine WB, Torralba TP et al (2001) A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporos Int 12:699–705PubMedCrossRef
130.
Zurück zum Zitat Bansal S, Pecina JL, Merry SP et al (2015) US Preventative Services Task Force FRAX threshold has a low sensitivity to detect osteoporosis in women ages 50–64 years. Osteoporos Int 26:1429–1433PubMedCrossRef Bansal S, Pecina JL, Merry SP et al (2015) US Preventative Services Task Force FRAX threshold has a low sensitivity to detect osteoporosis in women ages 50–64 years. Osteoporos Int 26:1429–1433PubMedCrossRef
131.
Zurück zum Zitat National Osteoporosis Foundation (NOF) (2008) Clinician’s Guide to prevention and treatment of osteoporosis. DC National Osteoporosis Foundation, Washington National Osteoporosis Foundation (NOF) (2008) Clinician’s Guide to prevention and treatment of osteoporosis. DC National Osteoporosis Foundation, Washington
132.
Zurück zum Zitat van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol (Oxford) 39:1383–1389CrossRef van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol (Oxford) 39:1383–1389CrossRef
133.
Zurück zum Zitat Orimo H, Hayashi Y, Fukunaga M et al (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. Jap J Bone Miner Metab 19:331–337CrossRef Orimo H, Hayashi Y, Fukunaga M et al (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. Jap J Bone Miner Metab 19:331–337CrossRef
134.
Zurück zum Zitat Fujiwara S, Nakamura T, Orimo H (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 19:429–435PubMedPubMedCentralCrossRef Fujiwara S, Nakamura T, Orimo H (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 19:429–435PubMedPubMedCentralCrossRef
135.
Zurück zum Zitat Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 7:390–406PubMedCrossRef Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 7:390–406PubMedCrossRef
136.
Zurück zum Zitat Royal College of Physicians (1999) Osteoporosis: clinical guidelines for the prevention and treatment. RCP, London Royal College of Physicians (1999) Osteoporosis: clinical guidelines for the prevention and treatment. RCP, London
137.
Zurück zum Zitat Hwang J, Chan D, Chen J, Cheng T, Wu C, Soong Y et al (2013) Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary. J Bone Miner Metab 31:1–7CrossRef Hwang J, Chan D, Chen J, Cheng T, Wu C, Soong Y et al (2013) Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary. J Bone Miner Metab 31:1–7CrossRef
138.
Zurück zum Zitat Compston J, Bowring C, Cooper A et al (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75:392–396PubMedCrossRef Compston J, Bowring C, Cooper A et al (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75:392–396PubMedCrossRef
139.
Zurück zum Zitat Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F (2009) Oden A and the National Osteoporosis Guideline Group (2008) Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK. Osteoporos Int 1395:499–1408, Erratum in Osteoporos Int 2009;20:499–502 CrossRef Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F (2009) Oden A and the National Osteoporosis Guideline Group (2008) Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK. Osteoporos Int 1395:499–1408, Erratum in Osteoporos Int 2009;20:499–502 CrossRef
140.
Zurück zum Zitat Compston J, Cooper A, Cooper C et al (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105–108PubMedCrossRef Compston J, Cooper A, Cooper C et al (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105–108PubMedCrossRef
141.
Zurück zum Zitat Johansson H, Oden A, Johnell O et al (2004) Optimization of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19:906–913PubMedCrossRef Johansson H, Oden A, Johnell O et al (2004) Optimization of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19:906–913PubMedCrossRef
142.
Zurück zum Zitat Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11:1–256CrossRef Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11:1–256CrossRef
143.
Zurück zum Zitat Johansson H, Kanis JA, Oden A, Compston J, McCloskey E (2012) A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int 23:907–915PubMedCrossRef Johansson H, Kanis JA, Oden A, Compston J, McCloskey E (2012) A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int 23:907–915PubMedCrossRef
144.
Zurück zum Zitat Kyriakos G, Vidal-Casariego A, Fernandez-Martinez MN et al (2015) Impact of the NOGG and NOF guidelines on the indication of bone mineral density in routine clinical practice. J Clin Densitom 18:533–538PubMedCrossRef Kyriakos G, Vidal-Casariego A, Fernandez-Martinez MN et al (2015) Impact of the NOGG and NOF guidelines on the indication of bone mineral density in routine clinical practice. J Clin Densitom 18:533–538PubMedCrossRef
145.
Zurück zum Zitat Chen JS, Simpson JM, Blyth FM, March LM (2014) Managing osteoporosis with FRAX (R) in Australia: proposed new treatment thresholds from the 45 &Up Study cohort. Bone 69:148–153PubMedCrossRef Chen JS, Simpson JM, Blyth FM, March LM (2014) Managing osteoporosis with FRAX (R) in Australia: proposed new treatment thresholds from the 45 &Up Study cohort. Bone 69:148–153PubMedCrossRef
146.
Zurück zum Zitat Johansson H, Kanis JA, McCloskey EV et al (2011) A FRAX (R) model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453–461PubMedCrossRef Johansson H, Kanis JA, McCloskey EV et al (2011) A FRAX (R) model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453–461PubMedCrossRef
147.
Zurück zum Zitat Zerbini CAF, Szejnfeld VL, Abergaria BH, McCloskey EV, Johansson H, Kanis JA (2015) Incidence of hip fracture in Brazil and the development of a FRAX model. Arch Osteoporos 10:224PubMedCrossRef Zerbini CAF, Szejnfeld VL, Abergaria BH, McCloskey EV, Johansson H, Kanis JA (2015) Incidence of hip fracture in Brazil and the development of a FRAX model. Arch Osteoporos 10:224PubMedCrossRef
148.
Zurück zum Zitat Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257–2276PubMedCrossRef Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257–2276PubMedCrossRef
149.
Zurück zum Zitat Niskanen L, Kettunen J, Koski A-M et al for the Finnish Medical Society Duodecim, Finnish Endocrine Society and Finnish Gynaecological Association (National) (2014) Osteoporosis. Current care guidelines. Suomalaisen Lääkäriseuran Duodecimin, Suomen Endokrinologiyhdistyksen ja Suomen Gynekologiyhdistyksen asettama työryhmä (2014) Osteoporoosi. http://www.terveysportti.fi/xmedia/hoi/hoi24065.pdf Accessed 26 Oct 2015 Niskanen L, Kettunen J, Koski A-M et al for the Finnish Medical Society Duodecim, Finnish Endocrine Society and Finnish Gynaecological Association (National) (2014) Osteoporosis. Current care guidelines. Suomalaisen Lääkäriseuran Duodecimin, Suomen Endokrinologiyhdistyksen ja Suomen Gynekologiyhdistyksen asettama työryhmä (2014) Osteoporoosi. http://​www.​terveysportti.​fi/​xmedia/​hoi/​hoi24065.​pdf Accessed 26 Oct 2015
150.
Zurück zum Zitat Briot K, Cortet B, Thomas T et al (2012) 2010 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 79:304–313PubMedCrossRef Briot K, Cortet B, Thomas T et al (2012) 2010 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 79:304–313PubMedCrossRef
152.
Zurück zum Zitat Grigorie D, Sucaliuc A, Johansson H, Kanis JA, McCloskey E (2013) FRAX-based intervention and assessment thresholds for osteoporosis in Romania. Arch Osteoporos 8:164PubMedCrossRef Grigorie D, Sucaliuc A, Johansson H, Kanis JA, McCloskey E (2013) FRAX-based intervention and assessment thresholds for osteoporosis in Romania. Arch Osteoporos 8:164PubMedCrossRef
158.
Zurück zum Zitat Bruyere O, Fossi M, Zegels D, Leonori L, Hiligsmann M, Neuprez A, Reginster JY (2013) Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria. Rheumatol Int 33:973–978PubMedCrossRef Bruyere O, Fossi M, Zegels D, Leonori L, Hiligsmann M, Neuprez A, Reginster JY (2013) Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria. Rheumatol Int 33:973–978PubMedCrossRef
159.
Zurück zum Zitat National Clinical Guideline Centre (2012) Osteoporosis: fragility fracture risk. Osteoporosis: assessing the risk of fragility fracture. Short clinical guideline—CG146 Evidence and recommendations August 2012. Published by the National Clinical Guideline Centre by the Royal College of Physicians, London National Clinical Guideline Centre (2012) Osteoporosis: fragility fracture risk. Osteoporosis: assessing the risk of fragility fracture. Short clinical guideline—CG146 Evidence and recommendations August 2012. Published by the National Clinical Guideline Centre by the Royal College of Physicians, London
160.
Zurück zum Zitat Shepstone L, Lenaghan E, Cooper et al (2012) A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the ‘SCOOP’ Study. Osteoporos Int 23:2507–2515PubMedCrossRef Shepstone L, Lenaghan E, Cooper et al (2012) A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the ‘SCOOP’ Study. Osteoporos Int 23:2507–2515PubMedCrossRef
161.
Zurück zum Zitat Strom O, Borgstrom F, Kleman M et al (2010) FRAX and its applications in health economics—cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 47:430–437PubMedCrossRef Strom O, Borgstrom F, Kleman M et al (2010) FRAX and its applications in health economics—cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 47:430–437PubMedCrossRef
162.
Zurück zum Zitat Strom O, Jonsson B, Kanis JA (2013) Intervention thresholds for denosumab in the UK using a FRAX(R)-based cost-effectiveness analysis. Osteoporos Int 24:1491–1502PubMedCrossRef Strom O, Jonsson B, Kanis JA (2013) Intervention thresholds for denosumab in the UK using a FRAX(R)-based cost-effectiveness analysis. Osteoporos Int 24:1491–1502PubMedCrossRef
163.
Zurück zum Zitat Michigan Quality Improvement Consortium Guideline (2014) Management and prevention of osteoporosis Michigan quality improvement consortium Accessed 25 Oct 2015 Michigan Quality Improvement Consortium Guideline (2014) Management and prevention of osteoporosis Michigan quality improvement consortium Accessed 25 Oct 2015
164.
Zurück zum Zitat Kanis JA, Adams J, Borgstrom F et al (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4–15PubMedCrossRef Kanis JA, Adams J, Borgstrom F et al (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4–15PubMedCrossRef
165.
Zurück zum Zitat Borgström F, Ström O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495–505PubMedCrossRef Borgström F, Ström O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495–505PubMedCrossRef
166.
Zurück zum Zitat Jonsson B, Strom O, Eisman JA et al (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22:967–982PubMedCrossRef Jonsson B, Strom O, Eisman JA et al (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22:967–982PubMedCrossRef
167.
Zurück zum Zitat Ivergard M, Strom O, Borgstrom F, Burge RT, Tosteson AN, Kanis J (2010) Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer. Bone 47:966–974PubMedCrossRef Ivergard M, Strom O, Borgstrom F, Burge RT, Tosteson AN, Kanis J (2010) Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer. Bone 47:966–974PubMedCrossRef
168.
Zurück zum Zitat Borgstrom F, Strom O, Coelho J et al (2010) The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int 21:339–349PubMedCrossRef Borgstrom F, Strom O, Coelho J et al (2010) The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int 21:339–349PubMedCrossRef
169.
Zurück zum Zitat Borgstrom F, Strom O, Kleman M et al (2010) Cost-effectiveness of bazedoxifene incorporating the FRAX(R) algorithm in a European perspective. Osteoporos Int 22:955–965PubMedCrossRef Borgstrom F, Strom O, Kleman M et al (2010) Cost-effectiveness of bazedoxifene incorporating the FRAX(R) algorithm in a European perspective. Osteoporos Int 22:955–965PubMedCrossRef
170.
Zurück zum Zitat Azagra R, Roca G, Martin-Sanchez et al (2015) FRAX thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population. Med Clin (Barc) 144:1–8CrossRef Azagra R, Roca G, Martin-Sanchez et al (2015) FRAX thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population. Med Clin (Barc) 144:1–8CrossRef
171.
172.
Zurück zum Zitat National Institute for Health and Clinical Excellence (2011a) Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. Technology appraisal TA160. http://guidance.nice.org.uk/TA160 Accessed 24 May 2011 National Institute for Health and Clinical Excellence (2011a) Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. Technology appraisal TA160. http://​guidance.​nice.​org.​uk/​TA160 Accessed 24 May 2011
173.
Zurück zum Zitat National Institute for Health and Clinical Excellence (2011b) Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Technology appraisal TA161. http://egap.evidence.nhs.uk/TA161 Accessed 24 May 2011 National Institute for Health and Clinical Excellence (2011b) Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Technology appraisal TA161. http://​egap.​evidence.​nhs.​uk/​TA161 Accessed 24 May 2011
174.
Zurück zum Zitat Kanis JA, McCloskey E, Jönsson B, Cooper A, Ström O, Borgström F (2010) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Arch Osteoporos 5:19–48CrossRef Kanis JA, McCloskey E, Jönsson B, Cooper A, Ström O, Borgström F (2010) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Arch Osteoporos 5:19–48CrossRef
175.
Zurück zum Zitat Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B (2007) Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model. Osteoporos Int 18:9–23PubMedCrossRef Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B (2007) Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model. Osteoporos Int 18:9–23PubMedCrossRef
176.
Zurück zum Zitat Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractures scores. Br Med J 339:b4229CrossRef Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractures scores. Br Med J 339:b4229CrossRef
177.
Zurück zum Zitat Chen P, Krege JH, Adachi JD et al (2009) Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner 24:495–502CrossRef Chen P, Krege JH, Adachi JD et al (2009) Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner 24:495–502CrossRef
178.
Zurück zum Zitat Sornay-Rendu E, Munoz F, Delmas PD, Chapurlat RD (2010) The FRAX® tool in French women: how well does it describe the real incidence of fracture in the OFELY cohort. J Bone Miner Res 25:2101–2107PubMedCrossRef Sornay-Rendu E, Munoz F, Delmas PD, Chapurlat RD (2010) The FRAX® tool in French women: how well does it describe the real incidence of fracture in the OFELY cohort. J Bone Miner Res 25:2101–2107PubMedCrossRef
179.
Zurück zum Zitat Bolland MJ, Siu AT, Mason BH et al (2011) Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res 26:420–427PubMedCrossRef Bolland MJ, Siu AT, Mason BH et al (2011) Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res 26:420–427PubMedCrossRef
180.
Zurück zum Zitat Ensrud KE, Lui LY, Taylor BC et al (2009) A comparison of prediction models for fractures in older women: is more better? Arch Intern Med 169:2087–2094PubMedPubMedCentralCrossRef Ensrud KE, Lui LY, Taylor BC et al (2009) A comparison of prediction models for fractures in older women: is more better? Arch Intern Med 169:2087–2094PubMedPubMedCentralCrossRef
181.
Zurück zum Zitat Tremollieres FA, Pouilles JM, Drewniak N, Laparra J, Ribot CA, Dargent-Molina P (2010) Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool. J Bone Miner Res 25:1002–1009PubMedPubMedCentralCrossRef Tremollieres FA, Pouilles JM, Drewniak N, Laparra J, Ribot CA, Dargent-Molina P (2010) Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool. J Bone Miner Res 25:1002–1009PubMedPubMedCentralCrossRef
182.
Zurück zum Zitat Donaldson MG, Palermo L, Schousboe JT, Ensrud KE, Hochberg MC, Cummings SR (2009) FRAX and risk of vertebral fractures: the fracture intervention trial. J Bone Miner Res 24:1793–1799PubMedCrossRef Donaldson MG, Palermo L, Schousboe JT, Ensrud KE, Hochberg MC, Cummings SR (2009) FRAX and risk of vertebral fractures: the fracture intervention trial. J Bone Miner Res 24:1793–1799PubMedCrossRef
183.
Zurück zum Zitat Hillier TA, Cauley JA, Rizzo JH (2011) The WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis? J Bone Miner Res 26:1774–1782PubMedPubMedCentralCrossRef Hillier TA, Cauley JA, Rizzo JH (2011) The WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis? J Bone Miner Res 26:1774–1782PubMedPubMedCentralCrossRef
184.
Zurück zum Zitat Pluskiewicz W, Adamczyk P, Franek E et al (2010) Ten-year probability of osteoporotic fracture in 2012 Polish women assessed by FRAX and nomogram by Nguyen et al.—conformity between methods and their clinical utility. Bone 46:1661–1667PubMedCrossRef Pluskiewicz W, Adamczyk P, Franek E et al (2010) Ten-year probability of osteoporotic fracture in 2012 Polish women assessed by FRAX and nomogram by Nguyen et al.—conformity between methods and their clinical utility. Bone 46:1661–1667PubMedCrossRef
185.
Zurück zum Zitat Tamaki J, Iki M, Kadowaki E, Sato Y et al (2011) The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int 25:71–76 Tamaki J, Iki M, Kadowaki E, Sato Y et al (2011) The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int 25:71–76
186.
187.
Zurück zum Zitat Sandhu SK, Nguyen ND, Center JR, Pocock NA, Eisman JA, Nguyen TV (2010) Prognosis of fracture: evaluation of predictive accuracy of the FRAX™ algorithm and Garvan nomogram. Osteoporos Int 21:863–871PubMedCrossRef Sandhu SK, Nguyen ND, Center JR, Pocock NA, Eisman JA, Nguyen TV (2010) Prognosis of fracture: evaluation of predictive accuracy of the FRAX™ algorithm and Garvan nomogram. Osteoporos Int 21:863–871PubMedCrossRef
188.
Zurück zum Zitat Leslie WD, Lix LM (2014) Comparison between various fracture risk assessment tools. Osteoporos Int 25:1–21PubMedCrossRef Leslie WD, Lix LM (2014) Comparison between various fracture risk assessment tools. Osteoporos Int 25:1–21PubMedCrossRef
189.
Zurück zum Zitat Kanis JA, Oden A, Johansson H, McCloskey E (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23:423–431PubMedCrossRef Kanis JA, Oden A, Johansson H, McCloskey E (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23:423–431PubMedCrossRef
190.
Zurück zum Zitat Marques A, Ferreira RJO, Santos E, Loza E, Carmona L, Pereira da Silva JA (2015) The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. Ann Rheum Dis. Downloaded from http://ard.bmj.com/ on 7 Aug 2015 Marques A, Ferreira RJO, Santos E, Loza E, Carmona L, Pereira da Silva JA (2015) The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. Ann Rheum Dis. Downloaded from http://​ard.​bmj.​com/​ on 7 Aug 2015
191.
Zurück zum Zitat Nayak S, Edwards DL, Saleh AA, Greenspan SL (2015) Systematic review and meta-analysis of the performance of clinical risk assessment instruments for screening for osteoporosis or low bone density. Osteoporos Int 26:1543–1554PubMedPubMedCentralCrossRef Nayak S, Edwards DL, Saleh AA, Greenspan SL (2015) Systematic review and meta-analysis of the performance of clinical risk assessment instruments for screening for osteoporosis or low bone density. Osteoporos Int 26:1543–1554PubMedPubMedCentralCrossRef
192.
Zurück zum Zitat Kanis JA, Odén A, Johansson H, McCloskey EV (2013) Pitfalls in the external validation of FRAX: response to Bolland et al. Osteoporos Int 24:391–392PubMedCrossRef Kanis JA, Odén A, Johansson H, McCloskey EV (2013) Pitfalls in the external validation of FRAX: response to Bolland et al. Osteoporos Int 24:391–392PubMedCrossRef
193.
Zurück zum Zitat Fraser LA, Langsetmo L, Berger C et al (2011) Fracture prediction and calibration of a Canadian FRAX tool: a population-based report from CaMos. Osteoporos Int 22:829–837PubMedCrossRef Fraser LA, Langsetmo L, Berger C et al (2011) Fracture prediction and calibration of a Canadian FRAX tool: a population-based report from CaMos. Osteoporos Int 22:829–837PubMedCrossRef
194.
Zurück zum Zitat Leslie WD, Lix LM, Johansson H et al (2010) Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res 25:2350–2358PubMedCrossRef Leslie WD, Lix LM, Johansson H et al (2010) Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res 25:2350–2358PubMedCrossRef
195.
Zurück zum Zitat Rubin KH, Abrahamsen B, Hermann AP et al (2011) Fracture risk assessed by fracture risk assessment tool (FRAX) compared with fracture risk derived from population fracture rates. Scand J Public Health 39:312–318PubMedCrossRef Rubin KH, Abrahamsen B, Hermann AP et al (2011) Fracture risk assessed by fracture risk assessment tool (FRAX) compared with fracture risk derived from population fracture rates. Scand J Public Health 39:312–318PubMedCrossRef
196.
Zurück zum Zitat Sund R, Honkanen R, Johansson H, Oden A, McCloskey EV, Kanis JA, Kröger H (2014) Evaluation of the FRAX model for the prediction of hip fractures in Kuopio, Finland. Calcif Tiss Int 95:39–45CrossRef Sund R, Honkanen R, Johansson H, Oden A, McCloskey EV, Kanis JA, Kröger H (2014) Evaluation of the FRAX model for the prediction of hip fractures in Kuopio, Finland. Calcif Tiss Int 95:39–45CrossRef
197.
Zurück zum Zitat Sund R (2007) Utilization of routinely collected administrative data in monitoring of aging-dependent hip fracture incidence. Epidemiol Perspect Innov 4:2PubMedPubMedCentralCrossRef Sund R (2007) Utilization of routinely collected administrative data in monitoring of aging-dependent hip fracture incidence. Epidemiol Perspect Innov 4:2PubMedPubMedCentralCrossRef
198.
Zurück zum Zitat Sund R (2006) Hip fracture incidence in Finland, 1998–2002. Duodecim 122(9):1085–1091PubMed Sund R (2006) Hip fracture incidence in Finland, 1998–2002. Duodecim 122(9):1085–1091PubMed
199.
Zurück zum Zitat Abrahamsen B, Vestergaard P, Rud B et al (2006) Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish osteoporosis prevention study. J Bone Miner Res 21:796–800PubMedCrossRef Abrahamsen B, Vestergaard P, Rud B et al (2006) Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish osteoporosis prevention study. J Bone Miner Res 21:796–800PubMedCrossRef
200.
Zurück zum Zitat Azagra R, Roca G, Zwart M, Encabo G (2011) Differences in the predictive values of the FRAX (TM) tool between the Spanish and United Kingdom population and considerations about the intervention threshold. Med Clin (Barc) 137(15):713–714CrossRef Azagra R, Roca G, Zwart M, Encabo G (2011) Differences in the predictive values of the FRAX (TM) tool between the Spanish and United Kingdom population and considerations about the intervention threshold. Med Clin (Barc) 137(15):713–714CrossRef
201.
Zurück zum Zitat Ettinger B, Ensrud KE, Blackwell T et al (2013) Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int 24:1185–1193PubMedCrossRef Ettinger B, Ensrud KE, Blackwell T et al (2013) Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int 24:1185–1193PubMedCrossRef
202.
Zurück zum Zitat Schwartz AV, Vittinghoff E, Bauer DC et al (2011) Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305:2184–2192PubMedPubMedCentralCrossRef Schwartz AV, Vittinghoff E, Bauer DC et al (2011) Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305:2184–2192PubMedPubMedCentralCrossRef
203.
Zurück zum Zitat Pressman AR, Lo JC, Chandra M, Ettinger B (2011) Methods for assessing fracture risk prediction models: experience with FRAX in a large integrated healthcare delivery system. J Clin Densitom 14:407–415PubMedCrossRef Pressman AR, Lo JC, Chandra M, Ettinger B (2011) Methods for assessing fracture risk prediction models: experience with FRAX in a large integrated healthcare delivery system. J Clin Densitom 14:407–415PubMedCrossRef
204.
205.
Zurück zum Zitat Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fractures. Osteoporos Int 7:407–413PubMedCrossRef Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fractures. Osteoporos Int 7:407–413PubMedCrossRef
206.
Zurück zum Zitat Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, the IOF CSA Working Group on Fracture Epidemiology (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277–1288PubMedPubMedCentralCrossRef Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, the IOF CSA Working Group on Fracture Epidemiology (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277–1288PubMedPubMedCentralCrossRef
207.
Zurück zum Zitat Kanis JA, Johansson H, Odén A, Dawson-Hughes B, Melton LJ 3rd, McCloskey EV (2010) The effects of a FRAX® revision for the USA. Osteoporos Int 21:35–40PubMedCrossRef Kanis JA, Johansson H, Odén A, Dawson-Hughes B, Melton LJ 3rd, McCloskey EV (2010) The effects of a FRAX® revision for the USA. Osteoporos Int 21:35–40PubMedCrossRef
208.
Zurück zum Zitat Brennan SL, Quirk SE, Hosking SM et al (2015) Is there an interaction between socioeconomic status and FRAX 10-year fracture probability determined with and without bone density measures? Data from the Geelong Osteoporosis Study of Female Cohort. Calcif Tissue Int 96:138–144PubMedCrossRef Brennan SL, Quirk SE, Hosking SM et al (2015) Is there an interaction between socioeconomic status and FRAX 10-year fracture probability determined with and without bone density measures? Data from the Geelong Osteoporosis Study of Female Cohort. Calcif Tissue Int 96:138–144PubMedCrossRef
209.
Zurück zum Zitat Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis J (2012) Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res 27:1243–1251PubMedCrossRef Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis J (2012) Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res 27:1243–1251PubMedCrossRef
210.
Zurück zum Zitat Johansson H, Odén A, Lorentzon M et al (2015) Is the Swedish FRAX model appropriate for immigrants to Sweden? Osteoporos Int 26:2617–2622PubMedCrossRef Johansson H, Odén A, Lorentzon M et al (2015) Is the Swedish FRAX model appropriate for immigrants to Sweden? Osteoporos Int 26:2617–2622PubMedCrossRef
211.
Zurück zum Zitat Leslie WD, Berger C, Langsetmo L et al (2011) Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int 22:1873–1883PubMedCrossRef Leslie WD, Berger C, Langsetmo L et al (2011) Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int 22:1873–1883PubMedCrossRef
212.
Zurück zum Zitat Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E (2009) BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int 20:1675–1682PubMedCrossRef Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E (2009) BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int 20:1675–1682PubMedCrossRef
213.
Zurück zum Zitat Yoon J, Kwon S-R, Lim M-J et al (2010) A comparison of three different guidelines for osteoporosis treatment in patients with rheumatoid arthritis in Korea. Korean J Intern Med 25:436–446PubMedPubMedCentralCrossRef Yoon J, Kwon S-R, Lim M-J et al (2010) A comparison of three different guidelines for osteoporosis treatment in patients with rheumatoid arthritis in Korea. Korean J Intern Med 25:436–446PubMedPubMedCentralCrossRef
214.
Zurück zum Zitat Kanis JA, McCloskey EV, Harvey NC, Johansson H, Leslie WD (2015) Intervention thresholds and the diagnosis of osteoporosis. J Bone Miner Res 30:1747–1753PubMedCrossRef Kanis JA, McCloskey EV, Harvey NC, Johansson H, Leslie WD (2015) Intervention thresholds and the diagnosis of osteoporosis. J Bone Miner Res 30:1747–1753PubMedCrossRef
215.
Zurück zum Zitat Leslie W, Morin S, Majumdar S et al (2016) Net reclassification Improvement with FRAX versus a simpler risk assessment system: more is more. J Bone Miner Res 30:S103 (Paper accepted Osteoporos Int, Feb 2016) Leslie W, Morin S, Majumdar S et al (2016) Net reclassification Improvement with FRAX versus a simpler risk assessment system: more is more. J Bone Miner Res 30:S103 (Paper accepted Osteoporos Int, Feb 2016)
216.
Zurück zum Zitat Kanis JA, Johansson H, Odén A, McCloskey EV (2012) The distribution of FRAX® based probabilities in women from Japan. J Bone Miner Metab 30:700–705PubMedCrossRef Kanis JA, Johansson H, Odén A, McCloskey EV (2012) The distribution of FRAX® based probabilities in women from Japan. J Bone Miner Metab 30:700–705PubMedCrossRef
217.
Zurück zum Zitat Borgstrom F, Johnell O, Kanis JA et al (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17:1459–1471PubMedCrossRef Borgstrom F, Johnell O, Kanis JA et al (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17:1459–1471PubMedCrossRef
218.
Zurück zum Zitat Oden A, McCloskey EV, Johansson H, Kanis JA (2013) Assessing the impact of osteoporosis on the burden of hip fractures. Calcif Tissue Int 92:42–49PubMedCrossRef Oden A, McCloskey EV, Johansson H, Kanis JA (2013) Assessing the impact of osteoporosis on the burden of hip fractures. Calcif Tissue Int 92:42–49PubMedCrossRef
219.
Zurück zum Zitat McCloskey EV, Johansson H, Harvey NC, Compston J, Kanis JA (2015) Online linkage of FRAX fracture risk assessment to management guidance is used by clinical practitioners. An analysis of access to National Osteoporosis Guideline Group Guidance in the UK (July 2013-June2014). J Bone Miner Res 30:S290–S291, (Paper accepted Osteoporos Int, June 2016) McCloskey EV, Johansson H, Harvey NC, Compston J, Kanis JA (2015) Online linkage of FRAX fracture risk assessment to management guidance is used by clinical practitioners. An analysis of access to National Osteoporosis Guideline Group Guidance in the UK (July 2013-June2014). J Bone Miner Res 30:S290–S291, (Paper accepted Osteoporos Int, June 2016)
220.
Zurück zum Zitat Crabtree NJ, Bebbington NA, Chapman DM et al (2010) Impact of UK National Guidelines based on FRAX(R)—comparison with current clinical practice. Clin Endocrinol 73:452–456 Crabtree NJ, Bebbington NA, Chapman DM et al (2010) Impact of UK National Guidelines based on FRAX(R)—comparison with current clinical practice. Clin Endocrinol 73:452–456
221.
222.
Zurück zum Zitat Brennan SL, Leslie WD, Leslie WD, Lix LM et al (2014) FRAX provides robust fracture prediction regardless of socioeconomic status. Osteoporos Int 25:61–69PubMedCrossRef Brennan SL, Leslie WD, Leslie WD, Lix LM et al (2014) FRAX provides robust fracture prediction regardless of socioeconomic status. Osteoporos Int 25:61–69PubMedCrossRef
223.
Zurück zum Zitat Kayan K, Johansson H, Oden A et al (2009) Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate. Osteoporos Int 20:2055–2061PubMedCrossRef Kayan K, Johansson H, Oden A et al (2009) Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate. Osteoporos Int 20:2055–2061PubMedCrossRef
224.
Zurück zum Zitat McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRef McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRef
225.
Zurück zum Zitat Harvey NC, Johansson H, Odén A et al (2016) FRAX predicts incident falls in elderly men. Findings from MrOs Sweden. Osteoporos Int 27:267–274PubMedCrossRef Harvey NC, Johansson H, Odén A et al (2016) FRAX predicts incident falls in elderly men. Findings from MrOs Sweden. Osteoporos Int 27:267–274PubMedCrossRef
226.
Zurück zum Zitat Johansson J, Harvey N, Odén A et al (2015) The predictive value of falls history for incident fracture decreases with time: MrOs Sweden. J Bone Miner Res 30:S424 Johansson J, Harvey N, Odén A et al (2015) The predictive value of falls history for incident fracture decreases with time: MrOs Sweden. J Bone Miner Res 30:S424
227.
Zurück zum Zitat Cauley JA, El-Hajj Fuleihan G, Luckey MM, FRAX® Position Development Conference Members (2011) Official positions for FRAX clinical regarding international differences. FRAX® International Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. J Clin Densitom 14:237–239PubMedCrossRef Cauley JA, El-Hajj Fuleihan G, Luckey MM, FRAX® Position Development Conference Members (2011) Official positions for FRAX clinical regarding international differences. FRAX® International Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. J Clin Densitom 14:237–239PubMedCrossRef
228.
Zurück zum Zitat van den Bergh JP, van Geel TA, Lems WF, Geusens PP (2010) Assessment of individual fracture risk: FRAX and beyond. Curr Osteoporos Rep 8(3):131–137PubMedPubMedCentralCrossRef van den Bergh JP, van Geel TA, Lems WF, Geusens PP (2010) Assessment of individual fracture risk: FRAX and beyond. Curr Osteoporos Rep 8(3):131–137PubMedPubMedCentralCrossRef
229.
Zurück zum Zitat Leslie WD, Majumdar SR, Lix LM et al (2012) High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int 23:391–397PubMedCrossRef Leslie WD, Majumdar SR, Lix LM et al (2012) High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int 23:391–397PubMedCrossRef
230.
Zurück zum Zitat Leslie WD, Morin S, Lix LM et al (2012) Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 23:75–85PubMedCrossRef Leslie WD, Morin S, Lix LM et al (2012) Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 23:75–85PubMedCrossRef
Metadaten
Titel
A systematic review of intervention thresholds based on FRAX
A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation
verfasst von
John A. Kanis
Nicholas C. Harvey
Cyrus Cooper
Helena Johansson
Anders Odén
Eugene V. McCloskey
The Advisory Board of the National Osteoporosis Guideline Group
Publikationsdatum
01.12.2016
Verlag
Springer London
Erschienen in
Archives of Osteoporosis / Ausgabe 1/2016
Print ISSN: 1862-3522
Elektronische ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-016-0278-z

Weitere Artikel der Ausgabe 1/2016

Archives of Osteoporosis 1/2016 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.